行業指南

人工智慧在製藥領域的應用

製藥工作中的人工智慧可以支援發現、臨床開發、製造、安全監測和監管分析。

聆聽此指南AI 語音敘述 · ~2 min

本頁閱讀時間約2分鐘
  1. 概述
  2. 重點摘要
  3. 深入探討
  4. Move from discovery to evidence carefully
  5. 現實世界的實施
  6. 付諸實踐
  7. 資料來源與延伸閱讀
  8. 不斷探索
  9. 常見問題

概述

Evidence must match the context of use and the consequences of error. A promising retrospective model is not automatically credible for a clinical or regulatory decision.

重點摘要

  1. State context of use and endpoint.
  2. Use risk-based validation and multidisciplinary review.
  3. Manage the model across its lifecycle.

深入探討

Define the intended use, population, endpoint, and decision boundary. A model prioritizing compounds for laboratory study differs from one used to inform a clinical submission. Preserve the distinction between exploratory hypotheses and evidence used to support safety or effectiveness. Use documented data provenance, quality controls, and appropriate validation. Check batch effects, missing measurements, site differences, and whether the outcome label is a meaningful proxy. For time-dependent or prospective decisions, use evaluation data that respects when information becomes available. FDA and EMA guiding principles emphasize human-centered design, risk-based approaches, context of use, multidisciplinary expertise, data governance, performance assessment, and lifecycle management. Treat these as a framework for evidence and accountability, not as a blanket approval of a model. Retain versioned protocols, model outputs, and review decisions. Monitor performance after deployment and define how a change in data, assay, or model triggers reassessment.

04工作範例

Move from discovery to evidence carefully

  1. Imagine a model ranking ten compounds for laboratory testing with a strong retrospective score.

  2. Before using it for a patient-safety decision, define the prospective endpoint and evaluate on data collected under that protocol.

  3. Record the uncertainty and require domain review at the new decision boundary.

它顯示了什麼

The constructed example separates exploratory prioritization from regulated evidence.

現實世界的實施

Hold out a study site when evaluating whether a biomarker model transfers.

Document context of use before using an AI result in a regulated submission.

付諸實踐

為什麼這很重要

  • 背景與規則. 產業背景決定了人工智慧創意能否與現實接觸。
  • 品質管控. 領域約束會影響可接受的錯誤率和監督模型。
  • 配裝選擇. 成功的部署使技術能力與第一線工作流程保持一致。

留意

  • 監理要求可能會使原本強大的原型失效。
  • 歷史資料可能會編碼損害特定社區的偏見。
  • 遺留系統可能會造成整合瓶頸和隱性成本。

後續步驟

  1. 讓領域專家參與從問題框架到評估的整個過程。
  2. 在啟動前設計審計追蹤和文件。
  3. 儘早驗證合規性和安全義務。
  4. 分階段推出,並有明確的停止和回滾標準。

資料來源與延伸閱讀

  1. FDAGuiding Principles of Good AI Practice in Drug Development

不斷探索

免費電子報

獲取每日 AI 簡報

每個工作日上午提供三則經過驗證的 AI 新聞,以淺顯易懂的英文撰寫。永久免費,無廣告。

每個工作日一封電子郵件。一鍵取消訂閱。我們絕不出售或分享您的地址。

測試一下自己

Take the AI in Pharma quiz

每個答案皆有即時回饋,通過課程後可獲得具備可驗證 ID 的可分享證書。

開始測驗

支持免費的 AI 教育。AI Understanding 是一個 501(c)(3) 非營利組織——絕無廣告,絕無付費牆。 捐款

常見問題

Does a strong discovery benchmark prove clinical credibility?

No. Evidence requirements depend on the intended use, data, endpoint, and risk of the decision.